An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts.

Efficacy of Zipalertinib in NSCLC Patients (pts) with EGFR Exon 20 Insertion (ex20ins) Mutations Who Received Previous Chemotherapy with or without amivantamab.

Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer.